Archives: Research

Research & Insights Content Type

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • Abandon Biosimilars as Biologics are Natural Monopolies

  • Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

    Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

  • List Price, Net Price, and the Rebate Caught in the Middle

  • Overview of Original Subscription Model and Features of LA and WA Proposals

    Overview of Original Subscription Model and Features of LA and WA Proposals

  • DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)

  • Expansion of the Medicare 340B Payment Program

  • The “Netflix Model” of Financing Hepatitis C Treatment

    The “Netflix Model” of Financing Hepatitis C Treatment

  • Cardiovascular Drugs Not Price Aligned with Value in US

  • Perspective on National Coverage Analysis of CAR-T Therapies

    Perspective on National Coverage Analysis of CAR-T Therapies